Encouragingly, the combination of ATRi and cisplatin also showed therapeutic efficacy in most, but not all, tumors in the autochthonous Vhl/Trp53/Rb1-deficient mouse ccRCC model. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.